Humacyte (HUMA) Gains from Investment Securities (2020 - 2026)

Humacyte (HUMA) has reported Gains from Investment Securities for 7 consecutive years, with -$4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 90.48% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$14.5 million (up 32.0% YoY), while the FY2025 annual figure was -$59.5 million, down 279.96% from the prior year.
• Gains from Investment Securities climbed to -$4.7 million in Q1 2026 per HUMA's latest filing, from -$10.3 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $58.2 million in Q4 2022 and bottomed at -$56.4 million in Q2 2022.
• Historically, Gains from Investment Securities has averaged -$1.3 million across 5 years, with a median of -$1.7 million in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities surged 100415.52% — and 2025, when it tumbled 1182.76%.
• Humacyte's Gains from Investment Securities stood at $58.2 million in 2022, then plunged by 102.9% to -$1.7 million in 2023, then plunged by 232.82% to -$5.6 million in 2024, then slumped by 83.93% to -$10.3 million in 2025, then soared by 54.13% to -$4.7 million in 2026.
• Business Quant data shows HUMA's Gains from Investment Securities at -$4.7 million in Q1 2026, -$10.3 million in Q4 2025, and -$4.9 million in Q3 2025.